Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C

References

• Manns M, Buti M, Gane E, et al. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006.
   PubMed Web of Science ®Google Scholar
• Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modeling study. Lancet Gastroenterol Hepatol. 2017;2:161–166.
   PubMed Web of Science ®Google Scholar
• Webster D, Klenerman P, Dusheiko G. Hepatitis C. Lancet. 2015;385:1124–1135.
   PubMed Web of Science ®Google Scholar
• Soriano V, Labarga P, De Mendoza C, et al. Acute hepatitis C virus re-infection in a heterosexual HIV-positive partner. Liver Int. 2016;36:763.
   PubMed Web of Science ®Google Scholar
• Sánchez C, Plaza Z, Vispo E, et al. Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain. Liver Int. 2013;33:1357–1362.
   PubMed Web of Science ®Google Scholar
• Hoornenborg E, Achterbergh R, Schim Van Der Loeff MF, et al. MOSAIC study group. MSM starting pre-exposure prophylaxis are at risk of hepatitis C virus infection. Aids. 2017;31:1603–1610.
   PubMed Web of Science ®Google Scholar
• Soriano V, Peters M, Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis. 2009;48:313–320.
   PubMed Web of Science ®Google Scholar
• Buti M, Riveiro-Barciela M, Esteban R. Management of direct-acting antiviral agent failures. J Hepatol. 2015;63:1511–1522.
   PubMed Web of Science ®Google Scholar
• Benítez-Gutiérrez L, Barreiro P, Labarga P, et al. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin Pharmacother. 2016;17:1215–1223.
   PubMed Web of Science ®Google Scholar
• Foster G, Afdhal N, Roberts S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–2617.
   PubMed Web of Science ®Google Scholar
• Johnson S, Thompson D, Raccor B. Hepatitis C virus genotype 3: update on current and emergent therapeutic interventions. Curr Infect Dis Rep. 2017;19:22.
   PubMed Web of Science ®Google Scholar
• Esposito I, Trinks J, Soriano V. Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opin Drug Metab Toxicol. 2016;12:1197–1209.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151:70–86.
   PubMed Web of Science ®Google Scholar
• Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504.
   PubMed Web of Science ®Google Scholar
• Molino S, Martin M. Hepatitis C virus resistance testing in genotype 1: the changing role in clinical utility. Ann Pharmacother. in press.
   Google Scholar
• Hézode C. Why I do not treat patients for mild disease. Liver Int. 2016;36(suppl 1):13–20.
   PubMed Web of Science ®Google Scholar
• Soriano V, Gallego L. Treating hepatitis C in injection drug users. Nat Rev Gastroenterol Hepatol. 2013;10:568–569.
   PubMed Web of Science ®Google Scholar
• Spaulding A, Anderson E, Khan M, et al. HIV and HCV in U.S. prisons and jails: the correctional facility as a bellwether over time for the community’s infections. AIDS Rev. in press.
   Google Scholar
• Yau A, Lee T, Ramji A, et al. Rate, delay and predictors of hepatitis C treatment in British Columbia. Can J Gastroenterol Hepatol. 2015;29:315–320.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev. 2012;14:168–178.
   PubMed Web of Science ®Google Scholar
• IDSA/AASLD. Recommendations for testing, managing, and treating hepatitis C. [cited 2017 May 25]. Available at http://www.hcvguidelines.org. .
   Google Scholar
• EASL. Recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153–194.
   PubMedGoogle Scholar
• Lawitz E, Poordad F, Wells J, et al. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus. Hepatology. 2017;65:1803–1809.
   PubMed Web of Science ®Google Scholar
• Kwo P, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. in press.
   Web of Science ®Google Scholar
• Wedemeyer H, Wyles D, Reddy R, et al. Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct acting antiviral regimen (C-SURGE). 52nd EASL. Amsterdam, Netherlands; 2017 April 19-23. Abstract book. Elsevier Publishers. [abstract PS-159].
   Google Scholar
• Keating G. Sofosbuvir: a review of its use in patients with chronic hepatitis C. Drugs. 2014;74:1127–1146.
   PubMed Web of Science ®Google Scholar
• Kirby B, Symonds W, Kearney B, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54:677–690.
   PubMed Web of Science ®Google Scholar
• Renet S, Chaumais MC, Antonini T, et al. Extreme bradychardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology. 2015;149:1378–1380.
   PubMed Web of Science ®Google Scholar
• Back D, Burger D. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology. 2015;149:1315–1317.
   PubMed Web of Science ®Google Scholar
• Mogalian E, German P, Kearney B, et al. Preclinical pharmacokinetics and first-in-human pharmacokinetics, safety, and tolerability of velpatasvir, a pangenotypic HCV NS5A inhibitor, in healthy subjects. Antimicrob Agents Chemother. 2017;61:e02084–16.
   PubMed Web of Science ®Google Scholar
• Mogalian E, Osinusi A, Shen G, et al. Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of sofosbuvir/velpatasvir fixed-dose combination tablet. Clin Pharm Ther. 2016;99(suppl):43–44.
   Google Scholar
• Sheng X, Casarez A, Cai R, et al. Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. Bioorg Med Chem Lett. 2012;22:1394–1396.
   PubMed Web of Science ®Google Scholar
• Barauskas O, Corsa A, Wang R, et al. Binding kinetics, potency, and selectivity of the hepatitis C virus NS3 protease inhibitors GS-9256 and vedroprevir. Biochem Biophys Acta. 2014;1840:3292–3298.
   PubMed Web of Science ®Google Scholar
• Mo H, Hedskog C, Lawitz E, et al. Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. Antiviral Res. 2017;140:151–157.
   PubMed Web of Science ®Google Scholar
• Yang H, Yang C, Wang Y, et al. Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256. Antivir Ther. in press.
   Google Scholar
• Rodriguez-Torres M, Glass S, Hill J, et al. GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study. J Viral Hepat. 2016;23:614–622.
   PubMed Web of Science ®Google Scholar
• Feld J, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–2607.
   PubMed Web of Science ®Google Scholar
• Curry M, O’Leary J, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–2628.
   PubMed Web of Science ®Google Scholar
• Wyles D, Brau N, Kottilil S, et al. Sofosbuvir/velpatasvir for 12 weeks in patients coinfected with HCV and HIV-1: the ASTRAL-5 Study. Presented at the 51st Annual Meeting of the European Association for the Study of the Liver, Barcelona, April 13-17, 2016. Abstract PS104.
   Google Scholar
• Everson G, Towner W, Davis M, et al. Sofosbuvir with velpatasvir in treatment-naive non-cirrhotic patients with genotype 1 to 6 hepatitis c virus infection: a randomized trial. Ann Intern Med. 2015;163:818–826.
   PubMed Web of Science ®Google Scholar
• Pianko S, Flamm S, Shiffman M, et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163:809–817.
   PubMed Web of Science ®Google Scholar
• Gane E, Shiffman M, Etzkorn K, et al. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in HCV patients previously treated with a direct-acting antiviral regimen. Hepatology. in press.
   Google Scholar
• Gane E, Schwabe C, Hyland R, et al. Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naïve or previously treated patients with HCV genotype 1 or 3 infections. Gastroenterology. 2016;151:448–456.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Reau N, Hinestrosa F, et al. Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with genotype 1 HCV infection in an open-label, phase 2 trial. Gastroenterology. 2016;151:893–901.
   PubMed Web of Science ®Google Scholar
• Gane E, Kowdley K, Pound D, et al. Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with HCV genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial. Gastroenterology. 2016;151:902–909.
   PubMed Web of Science ®Google Scholar
• Bourlière M, Gordon S, Ramji A, et al. Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks as a salvage regimen in NS5A inhibitor-experienced patients with genotype 1-6 infection: the phase 3 POLARIS-1 study. Boston, USA: American Association for the Study of Liver Disease (AASLD); 2016 November.
   Google Scholar
• Jacobson I, Lawitz E, Gane E, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153:113–122.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Flamm S, Tong M, et al. A randomized, controlled, phase 3 trial of sofosbuvir-velpatasvir-voxilaprevir or sofosbuvir-velpatasvir for 12 weeks in direct-acting antiviral-experienced patients with genotype 1-6 HCV infection: the POLARIS-4 study. Boston, USA: American Association for the Study of Liver Disease (AASLD); 2016 November.
   Google Scholar
• Cornberg M, MannsM. Hepatitis C: individualised medicine versus one pill fits all. Lancet Gastroenterol Hepatol. 2016;1:86–87.
   PubMedGoogle Scholar